Affiliation:
1. University of Pennsylvania School of Medicine, 421 Curie Boulevard, BRBII/III, PA, USA
2. University of Pennsylvania School of Medicine, 421 Curie Boulevard, BRBII/III, PA, USA.
Abstract
Ovarian cancer is the fourth leading cause of cancer deaths among women in the USA, despite its relatively low incidence of 50 per 100,000 women. Even though advances in therapy have been made, the ovarian cancer fatality-to-case ratio remains exceedingly high, owing to the lack of accurate tools to diagnose early-stage disease when cure is still possible. The most studied marker for ovarian cancer, CA125, is only expressed by 50–60% of patients with early-stage disease. Major efforts have been deployed to identify novel serum markers, yet no single marker has emerged as a serious competitor for CA125. Various groups are investing in combination approaches to increase the diagnostic value of existing markers, but many markers may still lie in underexplored areas of ovarian cancer biology, such as tumor vasculature environment and post-translational modifications (glycomics).
Subject
Biochemistry (medical),Clinical Biochemistry,Drug Discovery
Cited by
36 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献